A promising and clinically relevant finding was that reducing BRG1 expression sensitised both GICs and differentiated GBM tumour cells to the chemotherapeutic agent TMZ, likely due to the role BRG1 has in promoting DNA repair [61, 64]. This evidence concerns the gene SMARCA4 and glioblastoma.